Medivation price target raised to $95 from $80 at Credit Suisse Credit Suisse raised Medvation's price target ahead of PREVAIL trial data on January 30. The firm has increased confidence in the data and raised 2015 and beyond estimates. Shares are Outperform rated.
Medivation downgraded to Neutral from Buy at Goldman Goldman Sachs downgraded Medivation to Neutral saying current share levels fairly value Xtandi's opportunities in prostate and breast cancer. Goldman raised its price target for shares to $110 from $90 and believes Medivation's fundamentals remain strong.
Medivation upgraded to Buy at Canaccord As reported previously, Canaccord upgraded Medivation to Buy from Hold citing the pre-chemotherapy opportunity and meaningful incremental share gains of its Xtandi drug. Canaccord raised its price target on Medivation to $132 from $60.